STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Clinical trial NCT06880523 · RECRUITING
Trial details
- NCT number
- NCT06880523
- Sponsor
- Canadian Cancer Trials Group
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-21
- Primary completion
- 2028-01-31
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.